With acquisition, vision and deep pockets, Kriya Therapeutics eyes new day for gene therapy

One of the acquired programs — coupling gene therapy with the generic smoking cessation drug Chantix to quell hyperactive neurons in epilepsy patients — could be ready for a clinical trial next year or 2024.